Clinical trials: Active Tuberculosis
Pulmonary Tuberculosis, Gastro-Intestinal Disorder
Prokinetic Effect of Selected Nutraceuticals
Anti-Tuberculosis Treatment (ATT) is one of the effective treatments of tuberculosis but the use of drugs for a long time put an adverse effect on the gut and other organs of the body.
- Trial name
- NCT06157034
- Testing
- Zingier officinale powder, Carum carvi, L powder, Mentha spicata oil
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Allama Iqbal Open University Islamabad
Tuberculosis, HIV/AIDS
TB Reduction Through ART and TB Screening Project
Tuberculosis (TB) has overtaken HIV as the leading infectious cause of death worldwide and requires a major policy shift for it to be controlled in line with the WHO Stop-TB goal to "end TB".
- Trial name
- TREATS (NCT03739736)
- Testing
- Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Pulmonary Tuberculosis
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
The study assesses patients with cured pulmonary tuberculosis by compulsory notification data of Uberlândia (Minas Gerais state - Brazil) from 2012, 2013, 2014 and 2015. These patients will be invited by telephonic contact.
- Trial name
- NCT02736864
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Federal University of Uberlandia
Pulmonary Tuberculosis
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
The goal of this single-center, open-labelled, clinical trial in two groups aims to proof that a specific group of antibiotics (carbapenems) can be used to treat pulmonary tuberculosis if it is combined with another antibiotic…
- Trial name
- NCT05896930
- Testing
- Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV
- Where
- South Africa
- Volunteers
- 134 people
- Sponsor
- TASK Applied Science
HIV, Tuberculosis
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
The purpose of this study was to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
- Trial name
- NCT04518228
- Testing
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA)
- Where
- 23 sites in United States, Brazil and 6 more
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
to Assess Effect of Peer-led Education
Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia
The study might come up with valuable findings to address poor treatment outcome, poor quality of life, disability score and depressive symptoms. The findings may also be decreased health professional workload.
- Trial name
- DS-PTB (NCT07387601)
- Testing
- peer-led education
- Where
- Ethiopia
- Volunteers
- 250 people
- Sponsor
- Bahirdar University
Tuberculosis
Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342
The purpose of this study is to assess the safety and immunogenicity of two doses of the TB vaccine administered according to a 0, 1 month schedule.
- Trial name
- NCT01669096
- Testing
- GSK Biologicals' investigational TB vaccine GSK 692342
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Latent Tuberculosis
Economic Incentives and vDOT for Latent Tuberculosis Infection
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis.
- Trial name
- NCT05022862
- Testing
- Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
- Where
- United States
- Volunteers
- 399 people
- Sponsor
- Johns Hopkins University
HIV Infections, Tuberculosis
TB-LAM in the Diagnosis of TB
Tuberculosis (TB) is still the leading cause of death in HIV-infected patients. Early diagnosis of TB substantially improves the survival of HIV-infected patients.
- Conditions
- HIV Infections, Tuberculosis, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NCT04600232
- Testing
- Alere TB-LAM
- Volunteers
- 400 people
- Sponsor
- Shanghai Public Health Clinical Center
Tuberculosis, HIV I Infection
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
In sub-Saharan Africa, tuberculosis (TB) is the etiology of 25-50% of bloodstream infections (BSIs) and the leading cause of sepsis among people living with HIV.
- Conditions
- Tuberculosis, HIV I Infection, Sepsis
- Trial name
- ATLAS (NCT04618198)
- Testing
- Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 437 people
- Sponsor
- University of Virginia
Tuberculosis, HIV Infections
Tuberculosis in HIV Infected Patients in Uganda
This was a clinical trial in HIV infected patients with tuberculosis. The study assessed whether the addition of prednisolone, a type of steroid medication, to the standard treatment for tuberculosis improved immune and viral…
- Trial name
- NCT00057421
- Testing
- prednisolone
- Where
- Uganda
- Volunteers
- 190 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis, HIV
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
The purpose of this study is to use a cluster randomized trial to compare the effectiveness of linking the Quantiferon-gold in-tube test (QGIT) with routine CD4 testing to the routine use of the tuberculin skin test (TST), the…
- Trial name
- NCT02119130
- Testing
- QGIT
- Where
- 14 sites in South Africa
- Volunteers
- 3,506 people
- Sponsor
- Johns Hopkins University
HIV Infections, Tuberculosis
Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT
The aim of this study is to estimate the usefulness of QuantiFERON TB Gold In-Tube® and T-SPOT.TB® for the diagnosis of latent tuberculosis in HIV infected antiretroviral naive patients: 80 originated from low TB prevalence…
- Trial name
- NCT00647205
- Testing
- QuantiFERON TB Gold In-Tube, T-SPOT.TB®
- Where
- France
- Volunteers
- 240 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis, Tuberculosis
Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity
The purpose of the study is to estimate plasma drug levels ( free and total drug levels ) of rifampicin and other antituberculosis drugs and compare these drug levels in patients who develop drug induced hepatotoxicity versus…
- Trial name
- NCT01456845
- Where
- India
- Volunteers
- 110 people
- Sponsor
- All India Institute of Medical Sciences
Tuberculosis
Screening for TB in Pregnancy. on HIV-Infected Pregnant Women
Pregnant women who develop active Tuberculosis (TB) are at increased risk of poor maternal and infant outcomes. Our data from South Africa show that up to 3% of HIV-infected pregnant women have active TB , many with advanced…
- Trial name
- NCT02520973
- Testing
- Sputum sample
- Where
- South Africa
- Volunteers
- 1,400 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Tuberculosis, Extrapulmonary
Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease
The goal of this observational study is investigate the accuracy of the NanoDetect-TB kit in diagnosing tuberculosis (TB) using frozen serum and plasma samples collected from individuals suspected to have TB disease.
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Extrapulmonary, Tuberculosis Active
- Trial name
- NCT05981495
- Testing
- NanoDetect-TB
- Volunteers
- 460 people
- Sponsor
- NanoPin Technologies, Inc.
TB - Tuberculosis, HIV - Human Immunodeficiency Virus
Integrating Tuberculosis Treatment Into Community Pharmacies to Improve TB/HIV Outcomes in Uganda
Community pharmacies (CPs) have emerged as promising differentiated service delivery models for refilling antiretroviral therapy (ART) among people with human immunodeficiency virus (HIV).
- Trial name
- NCT07840651
- Testing
- The intervention is TB treatment delivery via community pharmacies for people with TB/HIV, Control Arm - standard of care
- Where
- 2 sites in Uganda
- Volunteers
- 124 people
- Sponsor
- Makerere University
Tuberculosis, HIV
TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
The purpose of this Phase I, open-label, randomized crossover trial is to investigate the pharmacokinetic interaction between steady-state lopinavir/ritonavir and single-dose TMC207 in healthy volunteers.
- Trial name
- NCT00828529
- Testing
- TMC207
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Tuberculosis, Pulmonary, HIV Coinfection
Pharmacist-Led Intervention to Improve TB Treatment Adherence
The goal of this clinical trial is to compare the adherence of co-morbid patients in control and experimental group The main question[s]it aims to answer are: 1.
- Trial name
- RA-15041995 (NCT06608069)
- Testing
- Educational counselling
- Where
- 2 sites in Malaysia
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Tuberculosis
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14. 15 participants will be recruited into each treatment arm in two sequential cohorts.
- Trial name
- ENABLE (NCT06748937)
- Testing
- Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- Where
- South Africa
- Volunteers
- 60 people
- Sponsor
- TASK Applied Science